🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. garetosmab

    Regeneron UK Limited

    Fibrodysplasia Ossificans Progressiva (FOP)

    phase 3 small molecule active

    1 trial

  2. garetosmab

    Regeneron UK Limited

    Fibrodyplasia Ossificans Progressiva (FOP)

    phase 3 small molecule terminated

    1 trial

  3. gemcitabine

    NORTHWEST BIOTHERAPEUTICS INC

    Non-Small Cell Lung Cancer

    phase 3 small molecule terminated

    1 trial

  4. gemcitabine and cisplatin (Induction chemotherapy)

    Sun Yat-sen University

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  5. gemcitabine and cisplatin (Induction chemotherapy)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  6. gemcitabine and cisplatin; docetaxel, cisplatin and fluorouracil

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  7. gemcitabine,nimotuzumab, toripalimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  8. granules for suspension, N-Acetyl-L-Leucine

    Intrabio Ireland Limited

    Ataxia Telangiectasia

    phase 3 small molecule active

    1 trial

  9. hydrocortisone (modified release), oral tablet 20 and 5 mg

    Takeda

    Adrenal Insufficiency

    phase 3 small molecule completed

    1 trial

  10. ianalumab

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  11. ianalumab s.c. q4w

    Novartis Pharmaceuticals

    Lupus Nephritis

    phase 3 small molecule active

    1 trial

  12. injectable naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    Opiate Dependence

    phase 3 small molecule completed

    1 trial

  13. inotuzumab ozogamicin

    Pfizer

    Lymphoma, Follicular

    phase 3 small molecule terminated

    1 trial

  14. insulin degludec

    Novo Nordisk A/S

    Diabetes

    phase 3 small molecule completed

    2 trials

  15. lactose monohydrate - 100,00 mg/tablet cellulose microcrystalline - 95,60 mg/tablet Croscarmellose sodium - 2,00 mg/tablet Magnesium stearate - 2,40 mg/tablet table coating - OPADRY 20A82938 Yellow - COLORCON, Asmenol, 10 mg, tabletki powlekane

    COLLEGIUM PHARMACEUTICAL, INC

    Ischemia of the lower limbs in the course of obstructive artery disease

    phase 3 small molecule active

    1 trial

  16. lebrikizumab

    Hoffmann-La Roche

    Asthma

    phase 3 small molecule completed

    2 trials

  17. lefamulin

    Nabriva Therapeutics Ireland DAC

    Community Acquired Pneumonia

    phase 3 small molecule completed

    1 trial

  18. levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets

    Teva Pharma GmbH

    Dysmenorrhea

    phase 3 small molecule completed

    2 trials

  19. linagliptine 5 mg

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  20. liraglutide

    Novo Nordisk A/S

    Metabolism and Nutrition Disorder

    phase 3 small molecule completed

    1 trial

  21. liraglutide

    Novo Nordisk A/S

    Diabetes

    phase 3 small molecule completed

    2 trials

  22. lixisenatide AVE0010

    Sanofi Pasteur

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  23. mCapOX plus Cetuximab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Colorectal Cancer (CRC)

    phase 3 small molecule active

    1 trial

  24. mRNA-4157, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    The participants must have a histologically confirmed diagnosis of resectable cSCC as the primary site of malignancy (metastatic skin involvement from another primary cancer or from an unknown primary cancer is not permitted).

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources